E. Ortega

发表

M. Leal, J. Moltó, F. Pulido, 2011, Clinical drug investigation.

Using evolutionary tools to refine the new hypervariable region 3 within the envelope 2 protein of hepatitis C virus.

A. Moya, M. Bracho, M. Torres-Puente, 2008, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Effect of antiviral treatment and host susceptibility on positive selection in hepatitis C virus (HCV).

A. Moya, M. Torres-Puente, F. González-Candelas, 2008, Virus research.

Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response

A. Moya, M. Bracho, M. Torres-Puente, 2008, Journal of viral hepatitis.

Contribution of insertions and deletions to the variability of hepatitis C virus populations.

A. Moya, M. Bracho, M. Torres-Puente, 2007, The Journal of general virology.

The changing face of HIV/AIDS in treated patients.

B. Clotet, E. Negredo, G. Sirera, 2009, Current HIV research.

Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

J. Mallolas, C. Quereda, F. Pulido, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice

C. Tural, J. Macías, Á. Burgos, 2010, HIV medicine.

Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients

S. Reus, J. Flores, M. Garcia-deltoro, 2017, AIDS.

Eradication of hepatitis C virus and non‐liver‐related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection

C. Tural, J. Mallolas, M. Crespo, 2017, Hepatology.

Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus

J. Macías, J. Pineda, A. Rivero, 2009, Hepatology.

Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment

B. Clotet, J. Pineda, M. Pérez-Elías, 2009, Antimicrobial Agents and Chemotherapy.

Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.

B. Clotet, J. Mallolas, M. Crespo, 2012, The Journal of infection.

Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus–coinfected patients

J. Macías, J. Pineda, A. Rivero, 2012, Hepatology.

[Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection].

E. Martinez, S. Johnston, F. Pulido, 2006, Enfermedades infecciosas y microbiologia clinica.

Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.

C. Tural, J. Mallolas, C. Quereda, 2013, Journal of hepatology.

Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients

D. Podzamczer, E. Negredo, J. Pineda, 2009, Journal of acquired immune deficiency syndromes.

Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations

C. Tural, J. Miro, V. Soriano, 2004, Journal of viral hepatitis.

Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients

B. Clotet, J. Mallolas, J. Macías, 2012, HIV clinical trials.

Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients.

C. Tural, M. Laguno, M. Crespo, 2010 .

Simeprevir in combination with sofosbuvir in treatment‐naïve and ‐experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open‐label, single‐arm study (PLUTO)

M. Buti, J. Calleja, M. Diago, 2017, Alimentary pharmacology & therapeutics.

Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.

J. Macías, J. Pineda, A. Rivero, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus‐coinfected patients

C. Tural, J. Macías, Á. Burgos, 2010, Journal of viral hepatitis.

Osteonecrosis in Patients Infected With HIV: Clinical Epidemiology and Natural History in a Large Case Series From Spain

J. Flores, F. Gutiérrez, C. Galera, 2006, Journal of acquired immune deficiency syndromes.

Epidemic dynamics of two coexisting hepatitis C virus subtypes.

A. Moya, M. Bracho, M. Torres-Puente, 2007, The Journal of general virology.

Genetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus Ribavirin

A. Moya, M. Bracho, M. Torres-Puente, 2008, PloS one.

Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference

J. Castilla, A. Moreno, C. Quereda, 2002, HIV clinical trials.

Analysis of hepatitis B precore region in serum and liver of chronic hepatitis B virus carriers.

J. Salmerón, E. Ortega, G. Moraleda, 1994, Journal of hepatology.

A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. The Hepatitis/HIV Spanish Study Group.

J. Castilla, E. Ortega, J. García-Samaniego, 1997, The Journal of infection.

Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain.

J. Pineda, A. Rivero, J. Portilla, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pegylated interferon a 2 a plus ribavirin versus pegylated interferon a 2 b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

C. Tural, J. Mallolas, C. Quereda, 2009 .

A new subtype of hepatitis C virus genotype 1: complete genome and phylogenetic relationships of an Equatorial Guinea isolate.

Andrés Moya, Enrique Ortega, Fernando González-Candelas, 2006, The Journal of general virology.

Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

C. Tural, J. Mallolas, C. Quereda, 2009, The Journal of antimicrobial chemotherapy.

Pegylated interferon a 2a plus ribavirin versus pegylated interferon a 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

C. Tural, J. Mallolas, C. Quereda, 2009 .

Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients

J. Macías, M. Márquez, E. Ortega, 2017, European Journal of Clinical Microbiology & Infectious Diseases.

Evidence of Recombination in Intrapatient Populations of Hepatitis C Virus

A. Moya, M. Bracho, M. Torres-Puente, 2008, PloS one.

Identification of a large, fast-expanding HIV-1 subtype B transmission cluster among MSM in Valencia, Spain

Enrique Ortega, David Navarro, Fernando González-Candelas, 2017, PloS one.

Expansion of the CRF19_cpx Variant in Spain.

M. Bracho, F. González-Candelas, D. Navarro, 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy].

B. Clotet, J. Gatell, J. Arribas, 2010, Enfermedades infecciosas y microbiologia clinica.

Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients

C. Tural, J. Macías, J. Pineda, 2013, AIDS.

Prevalence of CCR5-tropic HIV-1 Among Treatment-Experienced Individuals in Spain

B. Clotet, M. Leal, S. Moreno, 2009, HIV clinical trials.

Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment

A. Moya, M. Bracho, M. Torres-Puente, 2008, Journal of medical virology.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Genetic variability in hepatitis C virus and its role in antiviral treatment response

A. Moya, M. Bracho, M. Torres-Puente, 2007, Journal of viral hepatitis.

Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.

C. Tural, J. Mallolas, M. Crespo, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co‐infection

C. Tural, J. del Romero, J. Pineda, 2009, Journal of viral hepatitis.

Combined therapy of interferon plus ribavirin promotes multiple adaptive solutions in hepatitis C virus

A. Moya, M. Bracho, M. Torres-Puente, 2009, Journal of medical virology.

Avascular necrosis of the bone in HIV-infected patients: incidence and associated factors.

J. Flores, F. Gutiérrez, J. Portilla, 2002, AIDS.

Incidence of Hepatocellular Carcinoma in HIV-Infected Patients With Cirrhosis: A Prospective Study

J. Arribas, C. Quereda, J. Miró, 2014, Journal of acquired immune deficiency syndromes.

Transient Elastography for Predicting Liver-Related Events in CirrhoticHIV-Infected Patients

C. Tural, J. Miro, C. Quereda, 2017 .

Effects of eradication of HCV on cardiovascular risk and preclinical atherosclerosis in HIV/HCV-coinfected patients.

J. Bermejo, J. Navarro, C. Quereda, 2020, Journal of acquired immune deficiency syndromes.

The molecular epidemiology of HIV-1 in the Comunidad Valenciana (Spain): analysis of transmission clusters

Enrique Ortega, David Navarro, Fernando González-Candelas, 2017, Scientific Reports.

Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response

A. Moya, M. Bracho, M. Torres-Puente, 2008, Journal of viral hepatitis.

[Evaluation of the costs of transient elastography (FibroScan(®)) in the diagnosis of liver fibrosis in HIV patients with hepatitis C virus].

C. Tural, I. Oyagüez, M. Casado, 2012, Enfermedades infecciosas y microbiologia clinica.

Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

J. Mallolas, C. Quereda, F. Pulido, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus].

E. Negredo, F. Lozano, R. Palacios, 2015, Enfermedades infecciosas y microbiologia clinica.

Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain.

J. Pineda, A. Rivero, J. Portilla, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.